N-Propargylglycine Restores Survival by Preventing Calcium Oxalate Stone Formation, Tubular Injury, and Kidney Dysfunction in a Lethal Mouse Model of Primary Hyperoxaluria Type 2.

Oxalate Nephropathy in a Patient With Chronic Pancreatitis and Recent Surgery: A Clinical Conundrum.

Publisher Correction: Clinical burden, genetic heterogeneity, and diagnostic implications in primary hyperoxaluria type 2.

Coexistence of autosomal dominant polycystic kidney disease and primary hyperoxaluria type 3.

Genomic testing in pediatric urology: Implications for diagnosis and management.

Clinical burden, genetic heterogeneity, and diagnostic implications in primary hyperoxaluria type 2.

Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria.

A Case of Successful Kidney Transplant-Alone in Primary Hyperoxaluria Type 1 Using Lumasiran.

The Dawn of Precision Medicine in Pediatric Nephrology: Lumasiran and the Era of siRNA Therapies for Primary Hyperoxaluria Type 1.

The oxalobiome: unraveling the role of gut microbiota in oxalate metabolism and its implications for kidney health and disease management.

Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies.

Hyperoxaluria by the AGXT gene: a case report.

Current status of primary hyperoxaluria type 1 in Japan.

Don't think that combined liver kidney transplant can solve everything in primary hyperoxaluria type 1!

Ten tips on the work-up and management of CKD patients with nephrolithiasis.

Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1.

Nanobodies as therapies for loss-of-function misfolding diseases: the example of Primary Hyperoxaluria Type 1.

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Genetic Correction of the Most Common Mutation Causing Primary Hyperoxaluria Restores Enzyme Localization and Oxalate Metabolism.

LNP-mediated in vivo base editing corrects Agxt to cure primary hyperoxaluria type 1.

Oxalate nephropathy precipitated by linaclotide in a high-risk patient.

Surgical Management of Pediatric Primary Hyperoxaluria Type 1: An Eight-Patient Case Series in the Pre-siRNA Era.

Differential clinical characteristics of Chinese children with primary hyperoxaluria type 3.

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study.

Primary hyperoxaluria: insights into its clinical presentation, genetic mutations, and transplantation outcomes in a pediatric population in a tertiary care center.

Piperacillin Pharmacokinetics in a Pediatric Patient With Primary Hyperoxaluria Receiving High-Dose Continuous Dialysis Post Liver-Kidney Transplant.

Recognizing Primary Hyperoxaluria in Adults through Urine Oxalate Crystal Detection. Literature Review and Data Analysis.

Real-world burden of primary hyperoxaluria with chronic kidney disease in the United States: a retrospective administrative claims analysis.

[Primary hyperoxaluria-induced bilateral oxalate retinopathy: a case report].

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).

Transplant Without Borders: Clinical Outcomes and Challenges in Transborder Living Donor Pediatric Liver Transplantation in Jordan.

Urine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1.

Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.

Primary Hyperoxaluria Type 2 Masquerading as Chronic Kidney Disease of Unknown Origin in an Adolescent: A Case Report.

A reliable LC-MS/MS method for urinary oxalate determination and its comparison with analogous assays.

Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.

Global genetic prevalence estimates of primary hyperoxaluria are greater than previously reported.

Liver Transplantation in Childhood: A 2-Year Single Center Experience.

Whole Exome Sequencing in Chinese Pediatric Patients With Nephrolithiasis.

The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.

Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease.

RNA therapeutics in kidney diseases: prospects and current status.

Dietary Oxalate Nephropathy Due to Pureed Feeds.

Functional analysis of amino acid substitutions within human AGT1 in a cell-based platform to support the diagnosis of primary hyperoxaluria type 1.

Genetic Insights Into Nephrolithiasis and Renal Cancer Predisposition: Precision Medicine in Genes, Diagnosis, and Therapy.

Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings.

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1.

Hyperoxaluria: Diagnosis and Treatment.

Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1.

Chronic leg ulcers in a patient with Hyperoxaluria type 1: a rare and challenging diagnosis.

Normal urinary oxalate excretion in 4-hydroxy-2-oxo-glutarate aldolase 1 (HOGA1) deficient mice with AGT expression in peroxisomes and not in mitochondria.

Plasma Glycolate Levels Contribute to Drive the Decision of Isolated Kidney Transplantation in Dialyzed Patients with End-Stage Kidney Disease due to Primary Hyperoxaluria Type 1 Treated with Lumasiran: A Case Report.

Kidney stones and metabolic bone diseases not linked to parathyroid disfunction: a proposal for an integrated management.

[Administration of lumasiran in a child with infantile oxalosis undergoing chronic peritoneal dialysis: A case report].

A Minor Haplotype Variant Determines the Pathogenicity of the p.Ile279Thr Substitution in the Primary Hyperoxaluria Type 1 Gene, AGXT.

Primary hyperoxaluria type 1 diagnosis in adult dialysis patients: prediction model assessment in a group of Italian patients.

Primary hyperoxaluria type I diagnosed after a kidney transplant presenting with subcutaneous calcification: a case report of sodium thiosulfate treatment.

Updated Gene Therapy for Renal Inborn Errors of Metabolism.

Phenotypes and the Importance of Genetic Analysis in Adult Patients with Nephrolithiasis and/or Nephrocalcinosis: A Single-Center Experience.

Liver Transplantation in Primary Hyperoxaluria: A Single-Center 10-Year Experience.

Understanding Rare Kidney Stone Diseases: A Review.

Treatment preferences among individuals with primary hyperoxaluria type 1 (PH1): a real-world study.

Real-Life Data of 2-Year Lumasiran Use in the DAILY-LUMA Cohort.

The efficacy and safety of RNA interference for the treatment of primary hyperoxaluria: a systematic review and meta-analysis.

Hidden in CAKUT: Post-Transplant Diagnosis of Primary Hyperoxaluria Type 1 and Rescue Management Using Lumasiran.

Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease.

Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in the Netherlands.

Discovery of first-in-class human glycolate oxidase near infrared molecular rotor inhibitors (NIRGOi).

HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β-Catenin Signalling Pathway.

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial.

Short and Long-Term Outcomes of Liver Transplantation in Pediatric Patients With Inborn Errors of Metabolism: A Single-Center Study.

Fine-tuning circulating oxalate levels to improve transplant strategies in primary hyperoxaluria: what is the ideal threshold in pediatrics?

A Targeted Release Capsule of Lanthanum Carbonate: a New Efficient Cheap Treatment for Primary Hyperoxalurias.

Concomitant Treatment With Lumasiran and Nedosiran in a Child With Primary Hyperoxaluria Type 1.

Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K Working Group of the ERA and ESPN.

Genetic Diagnosis of Hyperoxaluria Type 3 Patients Using Haplotype Analysis.

[Management of patients with kidney stones].

Kidney Stones in Children: Causes, Consequences, and Concerns.

Modified J-shaped incision for combined pediatric liver-kidney transplants (CLKT): Focusing on the urological outcomes.

Management of genetically determined kidney stone disease: consensus from a panel of urologists and nephrologists.

Efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria: A systematic review and meta-analysis of randomized controlled trials.

Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).

Biochemical, structural, and cellular characterization of S-but-3-yn-2-ylglycine as a mechanism-based covalent inactivator of the flavoenzyme proline dehydrogenase.

Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1.

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria.

Synthesis and hLDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.

Spinal Cord Compression as the First Presentation of Primary Hyperoxaluria in a Patient With Kidney Failure: A Case Report and Literature Review.

Identification of a novel GRHPR mutation in primary hyperoxaluria type 2 and establishment of patient-derived iPSC line.

Biallelic Variant in the AGXT Gene in a Family Segregating Primary Hyperoxaluria; Accurate Genetic Diagnosis and Carrier Detection.

Cutting through the stones: Unlocking therapeutic potential with gene editing tools for primary hyperoxaluria type 1.

Application of four pricing models for orphan medicines: a case study for lumasiran.

Stenotrophomonas maltophilia in Hemodialysis: An Opportunistic Pathogen or a Malevolent Foe.

Effect of the allelic background on the phenotype of primary hyperoxaluria type I.

Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption.

The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding disease.

Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluria.

The possible association of two novel heterozygous GNB1 variants with obesity and metabolic disorders.

[Primary hyperoxaluria: results of a retrospective survey of the diagnostic practices of nephrologists].

Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.

Bilateral Exudative Retinal Detachments due to Primary Hyperoxaluria in a Child.

A narrative review of monogenic disorders causing nephrolithiasis and chronic kidney disease.

Importance of genetic study in primary hyperoxaluria type1. Case report.

Primary hyperoxaluria type 3: from infancy to adulthood in a genetically unique cohort.

Unveiling primary Hyperoxaluria type 1: a fortuitous discovery through bone marrow biopsy.

Second transplantation after kidney graft loss in primary hyperoxaluria type 2: a pedigree study and mutation analysis.

[Genetics in nephrology - any news?].

Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1.

Oxygen control in bioreactor drives high yield production of functional hiPSC-like hepatocytes for advanced liver disease modelling.

Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats.

Diet-induced hyperoxaluria: A case based mini-review.

Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption.

Simultaneous or sequential kidney-liver transplantation in primary hyperoxaluria.

A patent review of lactate dehydrogenase inhibitors (2014-present).

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.

Tracking Selective Internalization and Intracellular Dynamics of Modified Chitosan Polymeric Micelles of Interest in Primary Hyperoxaluria Diseases.

Can endogenous ethylene glycol production occur in humans? A detailed investigation of adult monozygotic twin sisters.

Infant primary hyperoxaluria type 1: A case report and literature review.

Late-onset retinal oxalosis in primary hyperoxaluria type 2.

Hot Hearts on Bone Scintigraphy Are Not All Amyloidosis: Hyperoxaluria-Associated Cardiomyopathy.

Luminescence-based complementation assay to assess target engagement and cell permeability of glycolate oxidase (HAO1) inhibitors.

Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.

Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1.

[Kidney involvement in rare hereditary diseases].

The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria.

Unveiling atypical diagnoses: when whole-genome analysis performed for refractory infantile hypomagnesemia reveals primary hyperoxaluria.

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.

[Clinical analysis of seven cases of primary hyperoxaluria type 1].

Unilateral Crystalline Ischemic Retinopathy Secondary to Primary Hyperoxaluria with Renal Failure and Oxalosis.

4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3.

Primary hyperoxaluria: Long-term outcomes of isolated kidney versus simultaneous liver/kidney transplant.

Modified by the Innovative Drugs and Strategies-Pattern of Selected Indications for Pediatric Liver Transplantation.

The Yield of Genetic Testing in Management of Nephrolithiasis.

Management of urinary stones: state of the art and future perspectives by experts in stone disease.

Recurrent symptomatic urolithiasis in a patient with cystic fibrosis.

Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions.

Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases.

Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs.

Diagnosis and management of primary hyperoxalurias: best practices.

Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.

Primary hyperoxaluria in adults and children: a nationwide cohort highlights a persistent diagnostic delay.

Clinical features and mutational spectrum of Chinese patients with primary hyperoxaluria type 2.

Simultaneous Liver Kidney Transplantation in a Primary Type 2 Hyperoxaluria With Corrected TOF and Severe Cardiomyopathy: A Case Report.

Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3.

Expanding the Genetic Spectrum of AGXT Gene Variants in Egyptian Patients with Primary Hyperoxaluria Type I.

Recurrent disease after pediatric renal transplantation.

A molecular journey on the pathogenesis of primary hyperoxaluria.

Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts.

Prevalence and characteristics of genetic disease in adult kidney stone formers.

Pathophysiology and management of enteric hyperoxaluria.

How We Treat Primary Hyperoxaluria Type 1.

Bone health in children with primary hyperoxaluria type 1 following liver and kidney transplantation.

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.

Gene editing: a near future for the treatment of genetic kidney diseases.

RNA therapeutics for disorders of excretory system.

RNA therapeutics for metabolic disorders.

A plain abdominal x-ray may direct the diagnosis of primary hyperoxaluria.

[Primary hyperoxaluria detected by bone marrow biopsy: A case report].

Primary hyperoxaluria: Description of a new oral finding and review of literature.

Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.

Case Report: effect of lumasiran treatment in a late preterm baby with antenatal diagnosis of primary hyperoxaluria type 1.

Comprehensive evaluation of patients with primary hyperoxaluria type 1: A nationwide study.

Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis.

Nephrocalcinosis can disappear in infants receiving early lumasiran therapy.

Lumasiran: A Review in Primary Hyperoxaluria Type 1.

Late Presentation of Primary Oxalosis, Microcrystalline Arthropathy, and Tumoral Calcinosis: A Case Report and a Literature Review.

Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants.

Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate.

Palmar papules as a manifestation of cutaneous oxalosis in primary hyperoxaluria: A case report and review of the literature.

Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.

[Primary hyperoxaluria type 1-a rare hereditary metabolic disorder as cause of livedo racemosa].

Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais.

Pediatric renal lithiasis in Spain: research, diagnostic and therapeutic challenges, and perspectives.

In vivo base editing rescues primary hyperoxaluria type 1 in rats.

Ophthalmic Sequelae of Late-Stage Primary Hyperoxaluria Type 1.

The Clinical and Pathological Characteristics of Patients with Oxalate Nephropathy.

Nedosiran: First Approval.

Combined liver-kidney transplantation in pediatric patients.

32-year-old diabetic patient with progressive vision loss and crystalline retinopathy.

Is Genotype the Major Outcome Parameter of Kidney Failure in Patients With Primary Hyperoxaluria Type 1?

A Rare Sparkle: A Case of Calcified Kidneys in a Young Infant With Renal Failure.

Young Male With End-Stage Renal Disease Due to Primary Hyperoxaluria Type 2: A Rare Presentation.

Clinical characteristics, genetic profile and short-term outcomes of children with primary hyperoxaluria type 2: a nationwide experience.

Primary Hyperoxaluria Screening and Monitoring: Quantitative Measurement of Plasma Oxalate by Gas Chromatography-Mass Spectrometry With High Sensitivity.

Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.

Hypercalcemia in an Infant with Primary Hyperoxaluria Type 2: A Novel Association.

Case series and literature review of primary hyperoxaluria type 1 in Chinese patients.

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.

Distinguishing characteristics of pediatric patients with primary hyperoxaluria type 1 in PEDSnet.

Primary hyperoxaluria: a case series.

Oxalate (dys)Metabolism: Person-to-Person Variability, Kidney and Cardiometabolic Toxicity.

Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1.

Genotype and Phenotype Characteristics of Chinese Pediatric Patients with Primary Hyperoxaluria.

A clinical screening algorithm for primary hyperoxaluria type 1 in adults on dialysis.

Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin.

Late Diagnosis of Primary Hyperoxaluria in an Adult Patient With End-Stage Renal Disease and Bicytopenia.

Idiopathic Oxalate Nephropathy Leading to End-Stage Kidney Disease: A Case Report.

Safety, Pharmacokinetics, and Exposure-Response Modeling of Nedosiran in Participants With Severe Chronic Kidney Disease.

Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.